Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024

被引：0

作者：

Antunes, Liliana ^{[1
]}

Rojas-Castro, Madelyn ^{[1
]}

Lozano, Marcos ^{[2
,3
]}

Martinez-Baz, Ivan ^{[3
,4
]}

Leroux-Roels, Isabel ^{[5
,6
,7
]}

Borg, Maria-Louise ^{[8
]}

Oroszi, Beatrix ^{[9
]}

Fitzgerald, Margaret ^{[10
]}

Duerrwald, Ralf ^{[11
]}

Jancoriene, Ligita ^{[12
]}

Machado, Ausenda ^{[13
]}

Petrovic, Goranka ^{[14
]}

Lazar, Mihaela ^{[15
]}

Souckova, Lenka ^{[16
]}

Bacci, Sabrina ^{[17
]}

Howard, Jennifer ^{[1
]}

Verdasca, Nuno ^{[18
]}

Basile, Luca ^{[19
]}

Castilla, Jesus ^{[3
,4
]}

Ternest, Silke ^{[5
]}

Dziugyte, Ausra ^{[8
]}

Turi, Gergo ^{[9
]}

Duffy, Roisin ^{[10
]}

Hackmann, Carolin ^{[11
]}

Kuliese, Monika ^{[20
]}

Gomez, Veronica ^{[13
]}

Makaric, Zvjezdana Lovric ^{[14
]}

Marin, Alexandru ^{[21
]}

Husa, Petr ^{[16
]}

Nicolay, Nathalie ^{[17
]}

Rose, Angela M. C. ^{[1
]}

VEBIS SARI VE network team

机构：

[1] EpiConcept, Paris, France

[2] Inst Hlth Carlos III, Natl Ctr Epidemiol, Madrid, Spain

[3] Consortium Biomed Res Epidemiol & Publ Hlth, Madrid, Spain

[4] Inst Salud Publ Navarra IdiSNA, Pamplona, Spain

[5] Ghent Univ Hosp, Dept Infect Control, Ghent, Belgium

[6] Univ Ghent, Ghent Univ Hosp, B-9000 Ghent, Belgium

[7] Ghent Univ Hosp, Ghent, Belgium

[8] Hlth Promot & Dis Prevent, Infect Dis Prevent & Control Unit IDCU, Msida, Malta

[9] Semmelweis Univ, Epidemiol & Surveillance Ctr, Natl Lab Hlth Secur, H-1085 Budapest, Hungary

[10] Hlth Protect Surveillance Ctr HPSC, Hlth Serv Execut, Dublin, Ireland

[11] Robert Koch Inst, Natl Reference Ctr Influenza, Berlin, Germany

[12] Vilnius Univ, Inst Clin Med, Fac Med, Clin Infect Dis & Dermatovenerol, Vilnius, Lithuania

[13] Natl Hlth Inst Doutor Ricardo Jorge, Dept Epidemiol, Lisbon, Portugal

[14] Croatian Inst Publ Hlth, Zagreb, Croatia

[15] Cantacuzino Natl Mil Med Inst Res Dev, Bucharest, Romania

[16] Masaryk Univ, Univ Hosp Brno, Brno, Czech Republic

[17] European Ctr Dis Prevent & Control, Stockholm, Sweden

[18] Natl Hlth Inst Doutor Ricardo Jorge, Dept Infect Dis, Lisbon, Portugal

[19] Generalitat Catalonia, Publ Hlth Agcy Catalonia, Subdirectorate Gen Surveillance & Response Publ Hl, Barcelona, Spain

[20] Lithuanian Univ Hlth Sci, Dept Infect Dis, Kaunas, Lithuania

[21] Dr Victor Babes Clin Hosp Infect & Trop Dis, Bucharest, Romania

来源：

INFLUENZA AND OTHER RESPIRATORY VIRUSES | 2025年 / 19卷 / 03期

关键词：

case-control study; elderly; severe acute respiratory infections (SARI); test-negative design; vaccine effectiveness;

D O I：

10.1111/irv.70081

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (>= 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.

引用

页数：7

共 15 条

[1] Antunes L., 2024, Early COVID19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe
[2] ECDC, 2023, Communicable Disease Threats Report (CDTR) Week 51, 1723 December 2023
[3] European Centre for Disease Prevention and Control (ECDC), 2024, European Respiratory Virus Surveillance Summary (ERVISS)
[4] European Centre for Disease Prevention and Control (ECDC), 2024, Interim COVID19 Vaccination Coverage in the EU/EEA During the 202324 Season Campaigns
[5] European Centre for Disease Prevention and Control (ECDC), 2024, Core Protocol for ECDC Studies of COVID- 19 Vaccine Effectiveness Against Hospitalisation With Severe Acute Respiratory Infection, Laboratory-Confirmed With SARS- CoV- 2 or With Seasonal Influenza-Version 3.0,
[6] Bias in vaccine effectiveness studies of clinically severe outcomes that are measured with low specificity: the example of COVID-19-related hospitalisation
Hansen, Christian Holm
[J]. EUROSURVEILLANCE, 2024, 29 (07)
[7] Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024
Huiberts, Anne J.
Hoeve, Christina E.
de Gier, Brechje
Cremer, Jeroen
van der Veer, Bas
de Melker, Hester E.
van de Wijgert, Janneke H. H. M.
van den Hof, Susan
Eggink, Dirk
Knoll, Mirjam J.
[J]. EUROSURVEILLANCE, 2024, 29 (10)
[8] Effectiveness of autumn 2023 COVID-19 vaccination and residual protection of prior doses against hospitalisation in England, estimated using a test-negative case-control study
Kirsebom, Freja C. M.
Stowe, Julia
Bernal, Jamie Lopez
Allen, Alex
Andrews, Nick
[J]. JOURNAL OF INFECTION, 2024, 89 (01)
[9] Ma K. C., 2024, Effectiveness of Updated 20232024 (Monovalent XBB.1.5) COVID19 Vaccination Against SARSCoV2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical SeverityIVY Network, 26 Hospitals, October 18, 2023March 9
[10] Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational
Moustsen-Helms, Ida Rask
Bager, Peter
Larsen, Tine Graakjaer
Moller, Frederik Trier
Vestergaard, Lasse Skafte
Rasmussen, Morten
Hansen, Christian Holm
[J]. LANCET INFECTIOUS DISEASES, 2024, 24 (09) : 964 - 973

← 1 2 →